Details for Patent: 12,144,889
Which drugs does patent 12,144,889 protect, and when does it expire?
Patent 12,144,889 protects DEXTENZA and is included in one NDA.
This patent has four patent family members in four countries.
Summary for Patent: 12,144,889
| Title: | Methods of treating allergic conjunctivitis |
| Abstract: | Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis. |
| Inventor(s): | Michael Goldstein |
| Assignee: | Ocular Therapeutix Inc |
| Application Number: | US17/673,331 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,144,889
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix | DEXTENZA | dexamethasone | INSERT;OPHTHALMIC | 208742-001 | Nov 30, 2018 | RX | Yes | Yes | 12,144,889 | ⤷ Start Trial | TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,144,889
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3177005 | ⤷ Start Trial | |||
| China | 115768385 | ⤷ Start Trial | |||
| European Patent Office | 4142664 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2021222117 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
